EGFR and non-small cell lung carcinoma: Icotinib hydrochloride is a novel EGFR-TKI developed in China; previous clinical trials using icotinib showed similar antitumor activity to other EGFR-TKIs in EGFR-mutated NSCLC patients [24–28] and it was subsequently approved by the Chinese State Food and Drug Administration in June 2011.